Episode Summary
Executive Summary: Peter Attia hosts David Sabatini and Matt Kaeberlein for a deep dive into rapamycin and mTOR, covering rapamycin’s discovery, mTORC1/2 biology, nutrient sensing, and why the drug may extend lifespan and healthspan across species. They emphasize the promise of intermittent, lower-dose use, the uncertainty around optimal dosing and tissue specificity, and the need for better biomarkers and clinical trials before broad human adoption.
Main Topics: Rapamycin discovery and historical development (Priority: 5/5): The discussion traces rapamycin from a soil sample from Rapa Nui to its isolation from Streptomyces hygroscopicus, naming, and eventual clinical approval decades later. The long delay between discovery and human use shaped both its reputation and research trajectory. mTOR biology and nutrient sensing (Priority: 5/5): Sabatini explains mTOR as a central nutrient-sensing kinase complex that links environmental nutrients to anabolic and catabolic states. The conversation covers mTORC1, mTORC2, lysosomal localization, amino acid sensing, and the role of leucine and arginine. Rapamycin mechanism, mTORC1 vs mTORC2, and dosing (Priority: 5/5): The speakers distinguish rapamycin’s allosteric inhibition of mTORC1 from chronic effects on mTORC2 formation, and discuss why intermittent dosing may preserve benefits while limiting toxicity. They also compare rapamycin with catalytic mTOR inhibitors and rapalogs. Longevity and healthspan evidence across species (Priority: 5/5): Kaeberlein reviews the reproducible lifespan and healthspan benefits of rapamycin in yeast, worms, flies, mice, dogs, and emerging primate data, arguing it is the most robust preclinical longevity drug known. The ITP mouse study is highlighted as a landmark. Human translational studies and immune rejuvenation (Priority: 5/5): The conversation centers on the 2009 and later human studies using everolimus/rapalogs in older adults, especially the Manick/Novartis work showing improved vaccine responses and low side effects at certain doses. This reframed rapamycin as an immune modulator rather than a pure immunosuppressant. Side effects, tissue specificity, and real-world use (Priority: 4/5): They discuss mouth sores, possible CNS penetration limits, variability in tissue exposure, and the uncertainty around whether rapamycin’s benefits come from direct tissue effects or systemic anti-inflammatory effects. Survey data on off-label users suggest relatively few major side effects. Future directions: biomarkers, companion animals, and reproductive aging (Priority: 4/5): The speakers call for better biomarkers of autophagy and inflammation, more dose-response studies, and larger trials in dogs, marmosets, and humans. They also note promising but still early work on ovarian aging, fertility, and periodontal disease.
Key Arguments: Rapamycin is uniquely important because it is the most reproducible pharmacologic intervention for extending lifespan and healthspan across multiple model organisms. mTOR is a master nutrient sensor that integrates amino acid availability, especially leucine and arginine, to regulate anabolic and catabolic programs. Rapamycin’s benefits likely come primarily from mTORC1 inhibition, but the exact contribution of mTORC2 inhibition, autophagy, and anti-inflammatory effects remains unresolved. Intermittent or lower-dose rapamycin may preserve benefits while reducing toxicity, but the optimal human dose, schedule, and tissue targets are still unknown. The 2009 ITP mouse study was pivotal because it showed lifespan extension when treatment began in middle age, making translation to older humans and dogs more plausible. Human everolimus studies in older adults showed improved vaccine responses and minimal side effects at some doses, suggesting rapalogs can modulate aging-related immune decline. The field needs better biomarkers, especially for autophagy and tissue-specific mTOR activity, because current tools are too crude to guide dosing or mechanism. Companion dogs and marmosets are valuable translational models because they age faster than humans and live in more realistic environments than lab mice.
Data Points: Rapamycin discovery soil sample: 1966–1967 - Sabatini described the original Easter Island soil samples that led to rapamycin isolation. Rapamycin chemical description paper: ~1971–1972 - The first chemical composition paper was cited as occurring in the early 1970s. FDA approval of rapamycin: 1999 - Rapamycin was approved for human use decades after discovery. ITP mouse study publication: 2009 - First major mouse lifespan study showing rapamycin extended lifespan. Mouse treatment start age in ITP: ~20 months - Treatment began in middle age due to formulation delays, a key translational finding. Rapamycin molecular weight: ~1000 Daltons - Sabatini noted rapamycin is a large small molecule and highly lipophilic. Dog aging trial enrollment target: 580 dogs - Kaeberlein described the TRIAD trial size. Dog trial treatment duration: 3 years - Primary lifespan/healthspan trial duration in pet dogs. Dog trial power: 9% change in lifespan - The study was powered to detect a 9% lifespan difference. Dog trial weight range: 40–110 pounds - Enrollment restricted to larger dogs because they age faster. Dog trial minimum age: 7 years - Dogs had to be at least seven years old and relatively healthy. Rapamycin user survey sample: 300+ users - Survey of off-label rapamycin users compared with nearly 200 non-users. Non-user comparison group: ~200 - Matched comparison cohort in the survey study. Most common side effect in survey: Mouth sores - Only statistically significant side effect difference reported among users. Mouth sore frequency: ~15% - Reported in the survey and referenced as similar to the Manick study. Everolimus vaccine study doses: 5 mg weekly, 20 mg weekly, 1 mg daily - Older adults received six weeks of everolimus before flu vaccination. Everolimus study duration: 6 weeks - Transient dosing before vaccination in older adults. RTB-101 trial outcome: Lower subsequent viral infections in post hoc analysis - Despite the pivotal trial being stopped early, later analysis suggested fewer influenza/coronavirus infections. Rapamycin dog pilot dosing: 0.1 mg/kg 3x/week; 0.05 mg/kg 3x/week; later 0.15 mg/kg weekly - Pilot studies informed the larger canine trial dosing. Human-equivalent mouse dose: ~0.1 mg/kg/day - Kaeberlein converted the ITP mouse dose to a human-equivalent daily dose. Rapamycin user common weekly dose: 6 mg weekly - Most off-label users in the survey reported this regimen. Highest weekly dose reported in survey: ~20 mg weekly - Upper end of self-reported off-label dosing.
Pivotal Quotes: "This is the protein that links the availability of nutrients in our environment to whether we're in a catabolic or an anabolic state." — David Sabatini: Sabatini defining mTOR’s core biological role. "It always works. And I would say without question, it is the most robust and reproducible drug... for impacting not only longevity but also health span." — Matt Kaeberlein: Kaeberlein explaining why rapamycin remains central to his research. "I think the field owes a lot of its credibility to the way you have approached it with scientific rigor being the highest priority." — Peter Atiyah: Attia praising Kaeberlein’s careful, non-commercial approach to rapamycin research.
Implications: Rapamycin remains one of the strongest longevity candidates, but listeners should not treat it as proven anti-aging therapy. The next breakthroughs depend on better dosing, biomarkers, and results from dogs, primates, and targeted human trials.
About Peter Attia Drive
Expert insight on health, performance, longevity, critical thinking, and pursuing excellence. Dr. Peter Attia (Stanford/Hopkins/NIH-trained MD) talks with leaders in their fields.